| Affymax files for approval of kidney disease drug - BusinessWeek |
|
|
BusinessWeek It is intended to treat anemia in patients who have chronic kidney failure and are on dialysis. Affymax and Takeda previously called the drug candidate Hematide. Takeda, a Japanese drugmaker, has marketing rights outside the US Affymax, of Palo Alto, ... Affymax Submits NDA For Peginesatide RTT News Takeda/Affymax file anaemia drug in USA Pharma Times Affymax and Takeda Announce the Submission of a New Drug Application for |